Drug Profile
ONO 7268MX2 - Ono Pharmaceutical
Alternative Names: ONO7268MX2; Peptide-based cancer vaccine - OncoTherapy Science/Ono PharmaceuticalLatest Information Update: 17 May 2018
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer Ono Pharmaceutical
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 03 May 2018 Immunovaccine is now called IMV
- 28 Jul 2017 Discontinued - Phase-I for liver cancer in Japan (SC) (Ono Pharmaceutical pipeline, July 2017)
- 01 Apr 2017 Ono Pharmaceutical completes a phase I trial in liver cancer (Late-stage disease) in Japan (SC) (JapicCTI142477)